No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

OrthoGrid Systems and nView medical Partnering Annnounce Partnership

Editor: What To Know

  • Announced today, nView medical, a leading innovator in 3D medical imaging, and OrthoGrid Systems, a global MedTech leader offering intraoperative alignment technologies, are partnering to provide integrated solutions that increase surgical accuracy and OR efficiency and improve patient outcomes.
  • PAO surgery aims to preserve the hip joint by repositioning the native acetabulum, a complex pediatric joint preservation surgery that aims to reduce or eliminate the risk of a future total hip replacement.
  • By integrating our applications within nView’s 3D imaging system, we are consolidating the number of devices required in the operating room, thus improving operating room efficiency, staff training, and the overall value proposition to the hospital.

Announced today, nView medical, a leading innovator in 3D medical imaging, and OrthoGrid Systems, a global MedTech leader offering intraoperative alignment technologies, are partnering to provide integrated solutions that increase surgical accuracy and OR efficiency and improve patient outcomes.

As the first step for implementation, the companies are executing a proof of concept for a periacetabular osteotomy (PAO) procedure, and, after completion, will expand to additional musculoskeletal procedures. PAO surgery aims to preserve the hip joint by repositioning the native acetabulum, a complex pediatric joint preservation surgery that aims to reduce or eliminate the risk of a future total hip replacement. OrthoGrid offers the first PAO-specific, imaging-based, surgical navigation application on the market.

“Many problems in orthopedic surgery are 3D problems. Currently, they are solved based on 2D imaging data,” says Dr. Chris Peters, Professor of Orthopaedics at the University of Utah and a renowned hip preservation specialist. “Being able to merge OrthoGrid’s Hip Preservation application with nView’s real-time, 3D, intraoperative imaging data would bring new and valuable information during critical surgical steps, such as the acetabular osteotomy and positioning.”

Both nView medical and OrthoGrid technologies are AI-driven, open platforms designed to work within the surgical theater to improve accuracy, workflow efficiency, and patient outcomes. With the nView 3D imaging data, planning can be achieved intraoperatively, reducing the need for preoperative planning. Similarly, postoperative alignment verification via x-rays may be avoided, and overall radiation exposure to young patients is expected to reduce drastically.

“We are thrilled to engage in this partnership with OrthoGrid, as we truly have aligned company missions: To enhance surgeons’ experience in the OR while simultaneously working to improve patient outcomes,” said Cristian Atria, Founder and CEO at nView Medical. “OrthoGrid’s expert knowledge of procedural steps and intraoperative problem-solving, along with their commitment to AI-driven, imaging-based automation, is an intuitive next step to further expand the opportunity behind real-time, 3D images. We look forward to seeing the immense impact combining these two innovations will have on musculoskeletal procedures in the years to come.”

“This partnership combines two technological needs within intraoperative imaging: Real-time, 3D imaging, and procedural decision making into one unique solution,” said Edouard Saget, Co-Founder, and Co-CEO at OrthoGrid Systems. “We seek to optimize the value equation in orthopedics, one of OrthoGrid’s long-term commitments. By integrating our applications within nView’s 3D imaging system, we are consolidating the number of devices required in the operating room, thus improving operating room efficiency, staff training, and the overall value proposition to the hospital. At the end of the day, we’re always working to make surgeons’ experience in the OR as seamless as possible.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy